• YM 58483 (BTP2): SOCE Research Context

  2026-10-05

  YM 58483, also called BTP2, is a pharmacological probe used to investigate store-operated calcium entry, immune-cell activation, and emerging fibrosis mechanisms. This overview compares supplier-reported activity with findings from a 2025 salivary-gland study, emphasizing what the evidence supports, where interpretation remains uncertain, and why BTP2 should not be treated as an ORAI2-specific or clinically validated therapy.

• Anlotinib and VEGFR2: Preclinical Evidence

  2026-10-05

  The reference study established anlotinib as a highly potent and selective VEGFR2 inhibitor with anti-angiogenic activity across biochemical, cellular, ex vivo, and animal models. Its findings support a vascular mechanism of tumor control, while also showing why strong preclinical activity should not be equated with direct tumor-cell cytotoxicity or clinical efficacy.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-10-04

  This case report and literature review describes radiographic regression of metastatic intra-abdominal desmoplastic small round cell tumor during anlotinib treatment after surgery and chemotherapy. The finding is hypothesis-generating rather than confirmatory, but it identifies a clinically relevant rationale for studying multi-target tyrosine kinase inhibition in a rare tumor with few standardized treatment options.

• Live-Dead Cell Staining Kit Overview

  2026-10-03

  The APExBIO Live-Dead Cell Staining Kit (SKU K2081) is described as a two-dye fluorescence product for distinguishing membrane-intact and membrane-compromised cells in cultured populations. No matched paper evidence was provided, so its performance, reproducibility, and suitability across models or instruments cannot be independently assessed here.

• HAUS1 in HCC: Immune Microenvironment and Proliferation

  2026-10-02

  The reference study integrates public transcriptomic, clinical, protein-expression, immune-infiltration, and siRNA data to define HAUS1 as a potential biomarker and functional driver in hepatocellular carcinoma. Its results connect elevated HAUS1 with adverse prognosis, tumor-cell proliferation, invasion, cell-cycle regulation, apoptosis, and immune-checkpoint context, while also highlighting the need for prospective and mechanistic validation.

• Bromodomain Inhibitor, (+)-JQ1 in Ferroptosis Assays

  2026-10-01

  Bromodomain Inhibitor, (+)-JQ1 provides a mechanistically focused way to study how BRD4 inhibition reshapes ferroptosis sensitivity. This guide translates recent ROS and FSP1 findings into assay design, interpretation, and cross-domain research decisions.

• Maraviroc (UK-427857): CCR5 Assay Workflows

  2026-10-01

  Build reproducible CCR5 experiments with Maraviroc, from HIV-1 entry inhibition and HIV tropism studies to extracellular-vesicle inflammation models. This practical guide combines product handling, assay controls, reference-driven EV workflows, and troubleshooting without overstating preclinical evidence.

• ABT-199 for Reliable BCL-2 Apoptosis Assays

  2026-09-30

  This scenario-driven guide explains how ABT-199 (GDC-0199), Bcl-2 inhibitor, potent and selective (SKU A8194), can improve experimental design for viability, proliferation, and apoptosis assays. It covers mechanism, DMSO handling, dose selection, data interpretation, and practical vendor-selection criteria for hematologic malignancy research.

• Amitriptyline HCl: Practical QC and Protocols

  2026-09-30

  Amitriptyline HCl (SKU B2231) provides a defined small-molecule reference for receptor inhibition, solution preparation, and quality control in neuropharmacology research. This guide supports controlled in vitro assay setup and exploratory mood disorder or neurodegenerative disease model work, but it should not be used to infer clinical efficacy or disease-modifying activity without independent validation.

• TMRE mitochondrial membrane potential assay kit guide

  2026-09-29

  Build a quantitative mitochondrial depolarization workflow for apoptosis, sodium-overload, tissue, and purified-mitochondria models. This guide pairs the TMRE mitochondrial Membrane Potential Assay Kit with CCCP controls, plate-based optimization, and mechanistic interpretation grounded in recent NECSO research.

• Bromodomain Inhibitor, (+)-JQ1: Assay Guide

  2026-09-29

  This scenario-based guide explains how Bromodomain Inhibitor, (+)-JQ1, SKU A1910, can improve interpretation and reproducibility in viability, proliferation, and apoptosis workflows. It connects BRD4 biology, solvent control, dose–time optimization, and product-handling decisions to published BET-inhibitor evidence.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma

  2026-09-28

  Shiota and colleagues developed a dCas9-based GFP reporter screen that identified chemically diverse HDAC inhibitors as suppressors of NUT-dependent transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomain activity, induction of differentiation, and improved tumor control in xenograft models, providing a mechanistic rationale for therapeutic investigation in NUT carcinoma.

• Thermogelling Hydrogel Improves Erythromycin for Keratitis

  2026-09-28

  Zheng and colleagues developed a thermosensitive BPOSS–BPEP hybrid hydrogel to address erythromycin’s poor aqueous solubility and short residence on the ocular surface. In a mouse model of Staphylococcus aureus keratitis, the drug-loaded formulation showed therapeutic activity and reported biocompatibility, supporting further study of hydrogel-based ocular delivery.

• VX-765 and the Logic of Inflammatory Cell Death

  2026-09-27

  Caspase-1 inhibition can help researchers separate inflammatory cytokine maturation from the broader consequences of cell death. This article connects VX-765 and its active metabolite VRT-043198 to a practical translational framework, while distinguishing caspase-1-dependent pyroptosis from the RNA Pol II-triggered apoptosis described in recent research.

• Rhodamine B for Nanomedicine Imaging Workflows

  2026-09-26

  Use Rhodamine B as a practical fluorescence readout for cell labeling and microscopy—not as a stand-in for therapeutic efficacy or proof of nanoparticle delivery. This workflow connects the trypsin-responsive pancreatitis nanomedicine study to careful tracer validation, with controls that distinguish cell-associated signal from free dye.

8038 records 1/536 page Next 12345 下5页 Last page